Vanda Pharmaceuticals Inc. 8-K

What Happened Vanda Pharmaceuticals (NASDAQ: VNDA) announced on April 22, 2026 that its Board expanded from six to seven members and appointed Charles C. Duncan, Ph.D., as a Class II director. Dr. Duncan’s initial term will expire at the Company’s 2026 annual meeting of stockholders. The Company filed this change in an 8‑K.

Key Details

• Board change effective April 22, 2026: size increased from six to seven directors; Charles C. Duncan appointed as Class II director.
• Equity compensation: initial restricted stock unit (RSU) award with a fixed grant-date value of $390,000 (number of shares to be determined under ASC 718); RSUs vest in four equal annual installments while serving, first vesting on April 22, 2027; full vesting on a change of control.
• Cash and ongoing equity pay: $50,000 annual cash fee payable quarterly; eligible for an annual RSU award with fixed grant-date value of $260,000 after each annual meeting beginning in 2026 (these annual RSUs vest one year from grant, or fully upon change of control).
• Governance and legal: Dr. Duncan enters the Company’s standard indemnification agreement; the Board has determined he is an independent director. No related-party transactions between Dr. Duncan and the Company since the start of the last fiscal year.

Why It Matters This 8‑K signals a governance change and adds an independent director to Vanda’s Board, which may affect board composition and oversight. The disclosed cash and equity package (initial $390k RSU grant plus $50k annual fee and potential $260k annual RSUs) shows the company’s standard outside-director compensation and the potential dilution/timing implications for shareholders (shares to be determined per ASC 718). The indemnification and independence determination are routine but important for director protections and governance disclosure.